Regulation of ornithine decarboxylase gene expression in MCF-7 breast cancer cells by antiestrogens.
Ornithine decarboxylase (ODC) is an enzyme intimately related to cell growth regulation. The metabolic products of ODC, the polyamines, are known to play a vital role in the structure and function of biological macromolecules including nucleic acids and proteins. The activity of ODC is stimulated by estrogens in their target cells. In order to gain insight into the molecular mechanism of action of antiestrogens in human breast cancer, we studied the effect of tamoxifen and 4-hydroxytamoxifen on the concentration of ODC mRNA, ODC activity, and the polyamine levels in a hormone-responsive breast cancer cell line, MCF-7. ODC mRNA concentration was reduced to 40% of the controls after 6 h of treatment of the cells with 100 nM 4-hydroxytamoxifen, but tamoxifen had no significant effect on ODC mRNA after treating with even 1 microM concentration for 36 h. ODC activity was, however, reduced to 40 and 75% of the controls after 24 h of treatment with 4-hydroxytamoxifen and tamoxifen, respectively. There was a significant reduction in the concentration of putrescine to 63% of control in tamoxifen-treated cells, but spermidine and spermine levels were not affected. With 4-hydroxytamoxifen, putrescine, spermidine, and spermine levels were reduced to 41, 62, and 79% of the control, respectively. In addition, exogenous putrescine was able to reverse the growth inhibitory effects of 4-hydroxytamoxifen. Overall, these results indicate that ODC and polyamine levels in MCF-7 cells are controlled by antiestrogens, and that suppression of polyamine biosynthesis plays a critical role in the growth inhibitory effects of antiestrogens.
Thomas
T
T
Department of Environmental and Community Medicine, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway 08854.
Trend
B
B
Butterfield
J R
JR
Jänne
O A
OA
Kiang
D T
DT
D015152:Blotting, Northern; D001943:Breast Neoplasms / Q000201:enzymology*; D002460:Cell Line; D004965:Estrogen Antagonists / Q000494:pharmacology*; D005260:Female; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D005796:Genes / Q000187:drug effects*; D006801:Humans; D009693:Nucleic Acid Hybridization; D009955:Ornithine Decarboxylase / Q000096:biosynthesis / Q000235:genetics*; D011073:Polyamines / Q000378:metabolism; D011700:Putrescine / Q000494:pharmacology; D012333:RNA, Messenger / Q000187:drug effects / Q000235:genetics; D013629:Tamoxifen / Q000494:pharmacology / Q000031:analogs & derivatives; D014407:Tumor Cells, Cultured / Q000187:drug effects
D004965:Estrogen Antagonists; D011073:Polyamines; D012333:RNA, Messenger; D013629:Tamoxifen; C016601:afimoxifene; D009955:Ornithine Decarboxylase; D011700:Putrescine